KR20180017104A - Peg화된 과립세포 콜로니 자극 인자(gcsf) - Google Patents

Peg화된 과립세포 콜로니 자극 인자(gcsf) Download PDF

Info

Publication number
KR20180017104A
KR20180017104A KR1020187000596A KR20187000596A KR20180017104A KR 20180017104 A KR20180017104 A KR 20180017104A KR 1020187000596 A KR1020187000596 A KR 1020187000596A KR 20187000596 A KR20187000596 A KR 20187000596A KR 20180017104 A KR20180017104 A KR 20180017104A
Authority
KR
South Korea
Prior art keywords
gcsf
peg
pegx
patient
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020187000596A
Other languages
English (en)
Korean (ko)
Inventor
에이브라함 아부초스키
로널드 쥐. 주빈
피터 제이. 부온템포
프리데리크 카조
Original Assignee
앰비오 파마슈티컬스, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 앰비오 파마슈티컬스, 엘엘씨 filed Critical 앰비오 파마슈티컬스, 엘엘씨
Publication of KR20180017104A publication Critical patent/KR20180017104A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/53Colony-stimulating factor [CSF]
    • C07K14/535Granulocyte CSF; Granulocyte-macrophage CSF
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020187000596A 2015-06-11 2016-06-13 Peg화된 과립세포 콜로니 자극 인자(gcsf) Withdrawn KR20180017104A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562174373P 2015-06-11 2015-06-11
US62/174,373 2015-06-11
US201562184042P 2015-06-24 2015-06-24
US62/184,042 2015-06-24
PCT/US2016/037278 WO2016201448A2 (en) 2015-06-11 2016-06-13 Pegylated granulocyte colony stimulating factor (gcsf)

Publications (1)

Publication Number Publication Date
KR20180017104A true KR20180017104A (ko) 2018-02-20

Family

ID=57504855

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187000596A Withdrawn KR20180017104A (ko) 2015-06-11 2016-06-13 Peg화된 과립세포 콜로니 자극 인자(gcsf)

Country Status (11)

Country Link
US (1) US20160361426A1 (enExample)
EP (1) EP3307757A4 (enExample)
JP (1) JP2018519359A (enExample)
KR (1) KR20180017104A (enExample)
CN (1) CN107949565A (enExample)
AU (1) AU2016277147A1 (enExample)
CA (1) CA2988988A1 (enExample)
IL (1) IL256167A (enExample)
MX (1) MX2017016103A (enExample)
RU (1) RU2018100425A (enExample)
WO (1) WO2016201448A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022011630A (es) * 2020-03-20 2022-12-02 Amgen Inc Determinación del extremo n libre del pegfilgrastim utilizando una proteasa ácida.

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020177688A1 (en) * 1988-12-22 2002-11-28 Kirin-Amgen, Inc., Chemically-modified G-CSF
US6565841B1 (en) * 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
AU1676992A (en) * 1991-03-18 1992-10-21 Enzon, Inc. Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US5981709A (en) * 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US6555660B2 (en) * 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
US6646110B2 (en) * 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
WO2003006501A2 (en) * 2001-07-11 2003-01-23 Maxygen Holdings, Ltd. G-csf conjugates
US7144978B2 (en) * 2002-01-15 2006-12-05 Pan Asia Bio Co., Ltd. Multidrop tree branching functional polyethylene glycol, methods of preparing and using same
ES2536710T3 (es) * 2002-03-25 2015-05-27 Arimed Inc. Nuevo uso terapéutico de LPC, ligandos agonistas específicos para el receptor G2A
US7892745B2 (en) * 2003-04-24 2011-02-22 Xdx, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
AU2004296855B2 (en) * 2003-12-03 2011-01-06 Ratiopharm Gmbh Glycopegylated Granulocyte Colony Stimulating Factor
CA2607844C (en) * 2005-06-01 2012-07-10 Maxygen Holdings Ltd. Pegylated g-csf polypeptides and methods of producing same
CA2617064A1 (en) * 2005-08-04 2007-02-15 Nektar Therapeutics Al, Corporation Conjugates of a g-csf moiety and a polymer
CU23556A1 (es) * 2005-11-30 2010-07-20 Ct Ingenieria Genetica Biotech Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico
US20110104100A1 (en) * 2007-10-04 2011-05-05 Medistem Laboratories, Inc. Compositions and methods of stem cell therapy for autism
CN101602801A (zh) * 2008-06-13 2009-12-16 杭州九源基因工程有限公司 聚乙二醇单修饰的重组人粒细胞集落刺激因子突变体
TW201138831A (en) * 2009-09-30 2011-11-16 Prolong Pharmaceuticals Inc Modified granulocyte colony stimulating factor (G-CSF)
WO2011075606A2 (en) * 2009-12-18 2011-06-23 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
CN104109235B (zh) * 2014-05-30 2017-07-18 厦门赛诺邦格生物科技股份有限公司 一种具有氮原子支化中心的单一官能化聚乙二醇、制备方法及其生物相关物质

Also Published As

Publication number Publication date
JP2018519359A (ja) 2018-07-19
EP3307757A4 (en) 2019-03-13
CA2988988A1 (en) 2016-12-15
WO2016201448A3 (en) 2017-02-09
AU2016277147A1 (en) 2018-01-18
US20160361426A1 (en) 2016-12-15
EP3307757A2 (en) 2018-04-18
IL256167A (en) 2018-04-30
RU2018100425A3 (enExample) 2019-11-21
CN107949565A (zh) 2018-04-20
RU2018100425A (ru) 2019-07-15
WO2016201448A2 (en) 2016-12-15
MX2017016103A (es) 2018-05-22

Similar Documents

Publication Publication Date Title
US7893019B2 (en) G-CSF site-specific mono-conjugates
KR100303810B1 (ko) 거핵구성장및분화를자극하기위한조성물및방법
CA2978330C (en) Conjugates of an il-7 moiety and a polymer
US12036283B2 (en) Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods
CN101328213A (zh) G-csf偶联物
ZA200105932B (en) GCSF conjugates.
KR20100082774A (ko) 폴리에틸렌 글리콜에 의해 변형된 인터페론 알파 2b, 이의 제조 방법 및 용도
KR101330338B1 (ko) Gm―csf 부분 및 중합체의 콘쥬게이트
KR20080027291A (ko) 피이지화된 지-씨에스에프 폴리펩타이드 및 그 제조방법
KR20100063108A (ko) 폴리에틸렌 글리콜에 의해 변형된 인터페론 알파 2a, 이의 합성 방법 및 용도
EP2174951B1 (en) Mutant of granulocyte-colony stimulating factor (G-CSF) and chemically conjugated polypeptide thereof
JP2008543304A (ja) ヒト顆粒球コロニー刺激因子イソ型(HumanGranulocyte−ColonyStimulatingFactorIsoforms)
KR20180017104A (ko) Peg화된 과립세포 콜로니 자극 인자(gcsf)
TW201138831A (en) Modified granulocyte colony stimulating factor (G-CSF)
EP1369429A1 (en) GCSF conjugates
MX2007015893A (en) Human granulocyte-colony stimulating factor isoforms

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180108

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination